
The TARGET Study
A global real-world retrospective study that confirms TheraSphere for HCC as safe and effective, demonstrating predictable clinical outcomes across a broad patient population in 8 countries.
Lam, M., Garin, E., Maccauro, M. et al. A global evaluation of advanced dosimetry in transarterial radioembolisation of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging (2022). https://doi.org/10.1007/s00259-022-05774-0
Study Objective
Establish the relationships between:
- Normal tissue adsorbed dose (NTAD) and occurrence of grade 3 or higher hyperbilirubinemia
- Tumour absorbed dose (TAD) and Objective Response Rate (ORR)
- TAD and Overall Survival (OS)
Study Design
Key Patient Characteristics
- Mainly Intermediate and Advanced HCC: 33% BCLC B and 55% BCLC C
- 7cm median target lesion
- 33% PVT
Dosimetry Approach
- Investigator review of patient chart and dosimetry calculation
- Retrospective dosimetry evaluation with multi-compartment approach using Simplicit90Y™ personalised dosimetry software to determine TAD and NTAD
Results
Tumour Absorbed Dose Was Predictive of Response1,2
Tumour Absorbed Dose Was Predictive of Overall Survival
Low Rate of ≥ Grade 3 Hyperbilirubinemia Confirms Safety of TARGET Study



Study Takeaways
|
|
|

Perform SIRT with TheraSphere™

SIMPLICIT90Y™
Embrace Y90
SIRT Personalised Dosimetry
SIRT Personalised Dosimetry

Virtual Events
View our latest virtual symposia and webinars on interventional oncology topics.

Stay up to date
Receive emails about the latest interventional oncology news, innovations and events.